Status:
COMPLETED
Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia
Lead Sponsor:
Visus Therapeutics
Conditions:
Presbyopia
Eligibility:
All Genders
45-80 years
Phase:
PHASE3
Brief Summary
Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
Detailed Description
Multicenter, Double-Masked, Randomized, Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF Topical Ophthalmic Solution With Emmetropic Phakic and Pseudophakic Presbyopia
Eligibility Criteria
Inclusion
- Male or female in good general health
- Must have presbyopia
Exclusion
- History of allergic reaction to the study drug or any of its components
- Any disease or medical condition that, in the opinion of the Investigator, would prevent the subject from participating in the study or might confound study results
Key Trial Info
Start Date :
March 30 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 10 2023
Estimated Enrollment :
182 Patients enrolled
Trial Details
Trial ID
NCT05270863
Start Date
March 30 2022
End Date
April 10 2023
Last Update
October 15 2024
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Visus Therapeutics Investigative Site
Glendale, California, United States, 91204
2
Visus Therapeutics Investigative Site
Rancho Cordova, California, United States, 95670
3
Visus Therapeutics Investigative Site
Jacksonville, Florida, United States, 32204
4
Visus Therapeutics Investigative Site
Morrow, Georgia, United States, 30260